Selective Targeting of Host CD70+ Alloreactive Cells to Prolong Allogeneic CAR T Cell Persistence
Summary
Allogene Therapeutics, Inc. filed USPTO Patent Application US20260109771A1, published April 23, 2026, covering CD70-binding proteins, engineered immune cells (CAR-T cells), and methods for treating cancer including solid tumors and hematologic tumors. The application also claims engineered cells expressing both a CD70 CAR and a second CAR targeting a cancer-characteristic molecule, with optional reduction of TRAC, CD52, or CD70 expression. The filing date was December 15, 2025.
“Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
The USPTO published patent application US20260109771A1, filed December 15, 2025, covering compositions and methods related to CD70-binding proteins and engineered immune cells. The application claims CAR-T cells engineered to co-express a CD70-targeting CAR and a second CAR targeting a cancer-associated antigen, with optional functional reduction of TRAC, CD52, or CD70. Methods of making and using the compositions, including methods of treating cancer patients by administering the engineered cells, are also disclosed.
Parties developing CAR-T therapies, cancer immunotherapies, or CD70-targeted oncology products should monitor the prosecution of this application to assess potential freedom-to-operate implications. Competitors working on allogeneic CAR-T platforms or CD70-targeting constructs may need to evaluate whether the claimed compositions and methods overlap with their own development programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE
Application US20260109771A1 Kind: A1 Apr 23, 2026
Assignee
Allogene Therapeutics, Inc.
Inventors
Elvin J. LAURON, Siler PANOWSKI, Barbra Johnson SASU, Cesar Adolfo SOMMER, Surabhi SRIVATSA SRINIVASAN, Thomas John VAN BLARCOM, Shanshan LANG
Abstract
Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.
CPC Classifications
C07K 16/2875 A61K 40/11 A61K 40/22 A61K 40/31 A61K 40/418 A61K 40/4211 A61K 40/4232 A61P 35/00 A61K 40/50 A61K 2239/28 C07K 2317/31
Filing Date
2025-12-15
Application No.
19420431
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.